Nulojix (belatacept): Risk Evaluation and Mitigation Strategy (REMS)

Audience: Transplantation, Nephrology Increased Risk of Post-transplant Lymphoproliferative Disorder (PTLD), predominantly involving the Central Nervous System (CNS), and Progressive Multifocal Leukoencephalopathy (PML)
ISSUE: Bristol-Myers Squibb…

Victoza (liraglutide [rDNA origin]) Injection: REMS – Risk of Thyroid C-cell Tumors, Acute Pancreatitis Audience: Endocrinology, Family Practice ISSUE: Novo Nordisk reminded healthcare professionals...
Yervoy (ipilimumab): Risk Evaluation and Mitigation Strategy (REMS) – Severe Immune-Mediated Adverse Reactions Audience: Hematology-Oncology ISSUE: Bristol-Myers Squibb informed healthcare professionals about the...

FREE Case Review

Defective DrugsAdverse reactions to medications on the market.

Personal InjuryPersonal injuries resulting from negligence may lead to significant medical expenses.

Toxic ExposureDangerous toxins linked to cancers, birth defects, and chronic respiratory problems.

DiseasesDangerous toxins linked to cancers, birth defects, and chronic respiratory problems.

Financial FraudsUnethical actions by large corporations may cause financial hardship.

Medical MalpracticeMedical errors or negligent health care resulting in injury or death.

Nulojix (belatacept): Risk Evaluation and Mitigation Strategy (REMS)

FREE Case Review

Trending Topics